Gilead Sciences, Inc. GILD
We take great care to ensure that the data presented and summarized in this overview for GILEAD SCIENCES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GILD
View all-
Black Rock Inc. New York, NY121MShares$15 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA119MShares$14.8 Billion0.21% of portfolio
-
State Street Corp Boston, MA59.1MShares$7.33 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA45.2MShares$5.61 Billion0.72% of portfolio
-
Dodge & Cox San Francisco, CA30.1MShares$3.74 Billion1.93% of portfolio
-
Capital Research Global Investors Los Angeles, CA30MShares$3.72 Billion0.65% of portfolio
-
Geode Capital Management, LLC Boston, MA29.9MShares$3.71 Billion0.22% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD26.5MShares$3.29 Billion0.31% of portfolio
-
Wellington Management Group LLP Boston, MA25.6MShares$3.18 Billion0.52% of portfolio
-
Morgan Stanley New York, NY23.7MShares$2.95 Billion0.17% of portfolio
Latest Institutional Activity in GILD
Top Purchases
Top Sells
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Insider Transactions at GILD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2025
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,745
-1.1%
|
$211,145
$121.34 P/Share
|
|
Dec 10
2025
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,693
+2.28%
|
-
|
|
Dec 10
2025
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,931
-0.85%
|
$596,651
$121.34 P/Share
|
|
Dec 10
2025
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,426
+1.76%
|
-
|
|
Dec 10
2025
|
Johanna Mercier Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,814
-1.63%
|
$219,494
$121.34 P/Share
|
|
Dec 10
2025
|
Johanna Mercier Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,842
+3.34%
|
-
|
|
Nov 28
2025
|
Jeffrey Bluestone Director |
SELL
Open market or private sale
|
Direct |
5,000
-35.92%
|
$625,000
$125.08 P/Share
|
|
Nov 28
2025
|
Jeffrey Bluestone Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+26.43%
|
$320,000
$64.92 P/Share
|
|
Nov 28
2025
|
Kelly A. Kramer Director |
SELL
Open market or private sale
|
Direct |
2,805
-67.69%
|
$356,235
$127.1 P/Share
|
|
Nov 28
2025
|
Kelly A. Kramer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,805
+40.37%
|
$227,205
$81.0 P/Share
|
|
Nov 28
2025
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-0.86%
|
$1,260,000
$126.38 P/Share
|
|
Nov 26
2025
|
Kelly A. Kramer Director |
SELL
Open market or private sale
|
Direct |
2,806
-67.7%
|
$356,362
$127.11 P/Share
|
|
Nov 26
2025
|
Kelly A. Kramer Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,806
+40.37%
|
$227,286
$81.0 P/Share
|
|
Nov 17
2025
|
Andrew D Dickinson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,500
-1.59%
|
$312,500
$125.23 P/Share
|
|
Nov 17
2025
|
Johanna Mercier Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
28,000
-10.57%
|
$3,528,000
$126.05 P/Share
|
|
Nov 17
2025
|
Johanna Mercier Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+15.61%
|
$1,650,000
$66.64 P/Share
|
|
Nov 12
2025
|
Deborah H Telman EVP, Corporate Affairs & GC |
SELL
Open market or private sale
|
Direct |
53,646
-24.84%
|
$6,598,458
$123.07 P/Share
|
|
Nov 12
2025
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
53,646
+18.08%
|
$3,486,990
$65.54 P/Share
|
|
Oct 28
2025
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-0.85%
|
$1,190,000
$119.18 P/Share
|
|
Oct 25
2025
|
Deborah H Telman EVP, Corporate Affairs & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
241
-0.55%
|
$28,920
$120.94 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 422K shares |
|---|---|
| Exercise of conversion of derivative security | 556K shares |
| Open market or private sale | 569K shares |
|---|---|
| Payment of exercise price or tax liability | 250K shares |